Oragenics Inc Is currently developing our antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, and have other product candidates, including SMaRT Replacement Therapy positioned for outlicensing or partnering.
Overcoming Antibiotic-Resistant Infections
Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly
healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an
OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including efficacy in an animal model for Clostridium difficile infection in enteritis.
OG716 for C. difficile Infection
OG716 is a molecule derived from our lantibiotic discovery and characterization platform that has shown positive results in nonclinical testing including an animal model for Clostridium difficile infection in enteritis.
COVID-19 vaccine Terra CoV-2
Oragenics, Inc. (NYSE:OGEN)
announced data from the National Institutes of Health (NIH) that demonstrated the stabilized prefusion spike protein CoV-2 S-2P (which is being developed as the COVID-19 vaccine Terra CoV-2) induced protective immunity in mice challenged with mouse-adapted SARS-CoV-2 virus (Dinnon3rd et al., 2020).
The following graphic shows that mice immunized with either 0.1 or 1 g of CoV-2 S-2P and combined with the TLR-4 agonist Sigma Adjuvant System (SAS) completed inhibited virus growth in the nasal cavities and lungs of mice following infection four weeks after their second immunization
compared to control mice immunized with placebo (PBS).